Evidence map›Paper›PMID 32750187›Full record

ArticleMolecular informatics2021

Insights on 3D Structures of Potential Drug-targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking.

Mariana S Fernandes, Francielly S da Silva, Ana Carolina S G Freitas, Eduardo B de Melo, Gustavo H G Trossini, Fávero R Paula

Abstract read
In one paragraph

Article in Molecular informatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mariana S FernandesCourse of Pharmacy, Federal University of Pampa (UNIPAMPA)., BR 472, km 592, P.O. Box 118, 97500-970, Uruguaiana-RS, Brazil.
Francielly S da SilvaCourse of Pharmacy, Federal University of Pampa (UNIPAMPA)., BR 472, km 592, P.O. Box 118, 97500-970, Uruguaiana-RS, Brazil.
Ana Carolina S G FreitasCourse of Pharmacy, Federal University of Pampa (UNIPAMPA)., BR 472, km 592, P.O. Box 118, 97500-970, Uruguaiana-RS, Brazil.
Eduardo B de MeloDepartment of Pharmacy, State University of West Paraná (UNIOESTE)., Universitária Street 2069, 85819-110, Cascavel-PR, Brazil.
Gustavo H G TrossiniDepartment of Pharmacy, University of São Paulo (USP)., Lineu Prestes Avenue 580, 05508-900, São Paulo-SP, Brazil.
Fávero R PaulaCourse of Pharmacy, Federal University of Pampa (UNIPAMPA)., BR 472, km 592, P.O. Box 118, 97500-970, Uruguaiana-RS, Brazil.ORCID http://orcid.org/0000-0002-6221-8318

Funding

CAPESFAPERGS 19/2551-0001784-7PDA-UNIPAMPA
6 · The paper itself

Abstract

The emergence of the COVID-19 has caused public health problems worldwide and there is no effective pharmacological treatment for this disease. Research on 3D models of proteins and the search for active molecular sites are important tools to assist in the discovery of effective antiviral drugs to combat COVID-19. To address this problem, the 3D protein structures of SARS-CoV 2 were analyzed and submitted to cavities research, evaluation of their druggabillity and liganbility, and applied to molecular docking studies with potential ligand candidates actually assayed against COVID-19. Eight druggable potential cavity sites were determined in model structures' PDB code, 6W4B, 6VWW, 6W01, 6M3M, and 6VYO, and these are the good alternatives to be characterized as targets for antiviral compounds. The good cavity model of the protease 3D structure was used in molecular docking, and this allowed verifying the theoric interactions of this protein and lopinavir and ritonavir antiviral drugs. These results may assist in the use of 3D protein models in drug design studies aiming to develop drugs against the COVID-19 pandemic.

Indexed as

Molecular Docking SimulationAntiviral AgentsCatalytic DomainComputer SimulationCoronavirus M ProteinsCoronavirus Nucleocapsid ProteinsCOVID-19COVID-19 Drug TreatmentDrug DesignHumansLigandsModels, MolecularPhosphoproteinsProtein BindingProtein ConformationSARS-CoV-2Antiviral AgentsCoronavirus M ProteinsCoronavirus Nucleocapsid ProteinsLigandsmembrane protein, SARS-CoV-2nucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Matrix Proteins3D StructuresCavity SearchCOVID19Molecular DockingSARS-CoV-2

Identifiers

PMID32750187
PMCPMC7436870

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.